Relation of Exercise Capacity to Risk of Development of Diabetes in Patients on Statin Therapy (the Henry Ford Exercise Testing Project)

Gabriel E. Shaya, Stephen P. Juraschek, David I. Feldman, Clinton A. Brawner, Jonathan K. Ehrman, Steven J. Keteyian, Mouaz H. Al-Mallah, Michael Blaha

Research output: Contribution to journalArticle

Abstract

High exercise capacity (EC) has been associated with a lower risk of incident diabetes, whereas statin therapy has been associated with a higher risk. We sought to investigate whether the association between EC and diabetes risk is modified by statin therapy. This retrospective cohort study included 47,337 patients without diabetes or coronary artery disease at baseline (age 53 ± 13 years, 48% women, 66% white) who underwent clinical treadmill stress testing within the Henry Ford Health System from January 1, 1991, to May 31, 2009. The patients were stratified by baseline statin use and estimated peak METs achieved during exercise testing. Hazard ratios for incident diabetes were calculated using Cox proportional hazards models adjusted for demographic characteristics, co-morbidities, pertinent medications, and stress test indication. We observed 6,921 new diabetes cases (14.6%) over a median follow-up period of 5.1 years (interquartile interval of 2.6 to 8.2 years). Compared with the statin group, the no-statin group achieved higher mean METs (8.9 ± 2.7 vs 9.6 ± 3.0, respectively; p <0.001). After adjustment for covariates, a higher EC was associated with a lower risk of incident diabetes, irrespective of statin use (p-interaction = 0.15). Each 1-MET increment was associated with an 8%, 8%, and 6% relative risk reduction in the total cohort, the no-statin, and the statin groups, respectively (95% confidence interval, 0.91 to 0.93, 0.91 to 0.93, and 0.91 to 0.96, respectively; p <0.001 for all). We conclude that a higher EC is associated with a lower risk of incident diabetes regardless of statin use.

Original languageEnglish (US)
Pages (from-to)769-773
Number of pages5
JournalAmerican Journal of Cardiology
Volume120
Issue number5
DOIs
StatePublished - Sep 1 2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Exercise
Therapeutics
Risk Reduction Behavior
Exercise Test
Proportional Hazards Models
Coronary Artery Disease
Cohort Studies
Retrospective Studies
Demography
Confidence Intervals
Morbidity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Relation of Exercise Capacity to Risk of Development of Diabetes in Patients on Statin Therapy (the Henry Ford Exercise Testing Project). / Shaya, Gabriel E.; Juraschek, Stephen P.; Feldman, David I.; Brawner, Clinton A.; Ehrman, Jonathan K.; Keteyian, Steven J.; Al-Mallah, Mouaz H.; Blaha, Michael.

In: American Journal of Cardiology, Vol. 120, No. 5, 01.09.2017, p. 769-773.

Research output: Contribution to journalArticle

Shaya, Gabriel E. ; Juraschek, Stephen P. ; Feldman, David I. ; Brawner, Clinton A. ; Ehrman, Jonathan K. ; Keteyian, Steven J. ; Al-Mallah, Mouaz H. ; Blaha, Michael. / Relation of Exercise Capacity to Risk of Development of Diabetes in Patients on Statin Therapy (the Henry Ford Exercise Testing Project). In: American Journal of Cardiology. 2017 ; Vol. 120, No. 5. pp. 769-773.
@article{8580b9190e4e472fa838ce073ffe564d,
title = "Relation of Exercise Capacity to Risk of Development of Diabetes in Patients on Statin Therapy (the Henry Ford Exercise Testing Project)",
abstract = "High exercise capacity (EC) has been associated with a lower risk of incident diabetes, whereas statin therapy has been associated with a higher risk. We sought to investigate whether the association between EC and diabetes risk is modified by statin therapy. This retrospective cohort study included 47,337 patients without diabetes or coronary artery disease at baseline (age 53 ± 13 years, 48{\%} women, 66{\%} white) who underwent clinical treadmill stress testing within the Henry Ford Health System from January 1, 1991, to May 31, 2009. The patients were stratified by baseline statin use and estimated peak METs achieved during exercise testing. Hazard ratios for incident diabetes were calculated using Cox proportional hazards models adjusted for demographic characteristics, co-morbidities, pertinent medications, and stress test indication. We observed 6,921 new diabetes cases (14.6{\%}) over a median follow-up period of 5.1 years (interquartile interval of 2.6 to 8.2 years). Compared with the statin group, the no-statin group achieved higher mean METs (8.9 ± 2.7 vs 9.6 ± 3.0, respectively; p <0.001). After adjustment for covariates, a higher EC was associated with a lower risk of incident diabetes, irrespective of statin use (p-interaction = 0.15). Each 1-MET increment was associated with an 8{\%}, 8{\%}, and 6{\%} relative risk reduction in the total cohort, the no-statin, and the statin groups, respectively (95{\%} confidence interval, 0.91 to 0.93, 0.91 to 0.93, and 0.91 to 0.96, respectively; p <0.001 for all). We conclude that a higher EC is associated with a lower risk of incident diabetes regardless of statin use.",
author = "Shaya, {Gabriel E.} and Juraschek, {Stephen P.} and Feldman, {David I.} and Brawner, {Clinton A.} and Ehrman, {Jonathan K.} and Keteyian, {Steven J.} and Al-Mallah, {Mouaz H.} and Michael Blaha",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.amjcard.2017.05.048",
language = "English (US)",
volume = "120",
pages = "769--773",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Relation of Exercise Capacity to Risk of Development of Diabetes in Patients on Statin Therapy (the Henry Ford Exercise Testing Project)

AU - Shaya, Gabriel E.

AU - Juraschek, Stephen P.

AU - Feldman, David I.

AU - Brawner, Clinton A.

AU - Ehrman, Jonathan K.

AU - Keteyian, Steven J.

AU - Al-Mallah, Mouaz H.

AU - Blaha, Michael

PY - 2017/9/1

Y1 - 2017/9/1

N2 - High exercise capacity (EC) has been associated with a lower risk of incident diabetes, whereas statin therapy has been associated with a higher risk. We sought to investigate whether the association between EC and diabetes risk is modified by statin therapy. This retrospective cohort study included 47,337 patients without diabetes or coronary artery disease at baseline (age 53 ± 13 years, 48% women, 66% white) who underwent clinical treadmill stress testing within the Henry Ford Health System from January 1, 1991, to May 31, 2009. The patients were stratified by baseline statin use and estimated peak METs achieved during exercise testing. Hazard ratios for incident diabetes were calculated using Cox proportional hazards models adjusted for demographic characteristics, co-morbidities, pertinent medications, and stress test indication. We observed 6,921 new diabetes cases (14.6%) over a median follow-up period of 5.1 years (interquartile interval of 2.6 to 8.2 years). Compared with the statin group, the no-statin group achieved higher mean METs (8.9 ± 2.7 vs 9.6 ± 3.0, respectively; p <0.001). After adjustment for covariates, a higher EC was associated with a lower risk of incident diabetes, irrespective of statin use (p-interaction = 0.15). Each 1-MET increment was associated with an 8%, 8%, and 6% relative risk reduction in the total cohort, the no-statin, and the statin groups, respectively (95% confidence interval, 0.91 to 0.93, 0.91 to 0.93, and 0.91 to 0.96, respectively; p <0.001 for all). We conclude that a higher EC is associated with a lower risk of incident diabetes regardless of statin use.

AB - High exercise capacity (EC) has been associated with a lower risk of incident diabetes, whereas statin therapy has been associated with a higher risk. We sought to investigate whether the association between EC and diabetes risk is modified by statin therapy. This retrospective cohort study included 47,337 patients without diabetes or coronary artery disease at baseline (age 53 ± 13 years, 48% women, 66% white) who underwent clinical treadmill stress testing within the Henry Ford Health System from January 1, 1991, to May 31, 2009. The patients were stratified by baseline statin use and estimated peak METs achieved during exercise testing. Hazard ratios for incident diabetes were calculated using Cox proportional hazards models adjusted for demographic characteristics, co-morbidities, pertinent medications, and stress test indication. We observed 6,921 new diabetes cases (14.6%) over a median follow-up period of 5.1 years (interquartile interval of 2.6 to 8.2 years). Compared with the statin group, the no-statin group achieved higher mean METs (8.9 ± 2.7 vs 9.6 ± 3.0, respectively; p <0.001). After adjustment for covariates, a higher EC was associated with a lower risk of incident diabetes, irrespective of statin use (p-interaction = 0.15). Each 1-MET increment was associated with an 8%, 8%, and 6% relative risk reduction in the total cohort, the no-statin, and the statin groups, respectively (95% confidence interval, 0.91 to 0.93, 0.91 to 0.93, and 0.91 to 0.96, respectively; p <0.001 for all). We conclude that a higher EC is associated with a lower risk of incident diabetes regardless of statin use.

UR - http://www.scopus.com/inward/record.url?scp=85023772723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023772723&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2017.05.048

DO - 10.1016/j.amjcard.2017.05.048

M3 - Article

C2 - 28716336

AN - SCOPUS:85023772723

VL - 120

SP - 769

EP - 773

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -